How should a newborn with a soft, mobile subcutaneous mass suspected to be fat necrosis or a lipoma be evaluated and managed?

Evaluation and Management of Suspected Fat Necrosis or Lipoma in Newborns

For a newborn with a soft, mobile subcutaneous mass, subcutaneous fat necrosis of the newborn (SCFN) is far more likely than lipoma and requires immediate evaluation with ultrasound and serum calcium monitoring, as hypercalcemia occurs in 100% of monitored cases and can cause serious complications including nephrocalcinosis and acute kidney injury. 1

Initial Clinical Assessment

Key distinguishing features to identify:

• SCFN characteristics: Firm, indurated subcutaneous plaques or nontender mobile nodules with possible skin discoloration (purple or erythematous), appearing in the first 6 weeks of life, predominantly on the upper back, shoulders, cheeks, buttocks, and limbs 2, 3
• Risk factors for SCFN: Full-term or post-term birth (84% of cases), perinatal asphyxia, delivery complications (53% of cases), cesarean section (58%), therapeutic hypothermia, maternal gestational diabetes, or maternal hypertensive disease 1, 3
• True lipomas are exceedingly rare in neonates and would not present with the clinical context described above

Diagnostic Imaging Approach

Ultrasound is the definitive initial imaging modality for superficial neonatal masses:

• For suspected SCFN: US shows hyperechoic and avascular subcutaneous tissue with possible acoustic shadows from calcifications 2, 4
• For suspected lipoma (if clinical features atypical): US demonstrates no or minimal acoustic shadowing, minimal vascularity, and simple curved echogenic lines within an encapsulated mass with sensitivity of 94.1% and specificity of 99.7% 5
• US advantages: Best resolution for superficial lesions, no sedation required, no ionizing radiation, and can differentiate solid from cystic lesions 2

Radiographs should precede ultrasound as the fundamental initial assessment, though they may be unrewarding for small, non-mineralized superficial masses 5

When US or clinical features are atypical, further imaging with MRI is required 5

Critical Laboratory Monitoring for SCFN

Immediate and serial calcium monitoring is mandatory:

• Obtain initial ionized calcium level when SCFN is suspected 1
• Monitor for the first 3 months of life as most hypercalcemia (86%) and peak levels (59%) occur within the first 28 days, but no cases developed hypercalcemia after 3 months 1
• 100% of infants with SCFN who had laboratory monitoring developed hypercalcemia 1
• 89.3% of hypercalcemic cases showed suppressed parathormone levels 3

Additional laboratory screening:

• Hypoglycemia, hypertriglyceridemia, thrombocytopenia, and anemia should be evaluated at diagnosis and during follow-up 4, 6

Management Algorithm Based on Calcium Levels

For asymptomatic hypercalcemia with ionized calcium <1.5 mmol/L:

• Outpatient monitoring with serial calcium levels
• Low likelihood of complications in this range 1

For ionized calcium 1.5-1.6 mmol/L (62% of cases):

• Close outpatient monitoring
• Consider dietary modifications (low calcium formula, avoid vitamin D supplementation)

For symptomatic hypercalcemia, markedly elevated levels (>1.6 mmol/L), or persistently elevated levels (>6 months):

• Coordinate care with pediatric endocrinology or nephrology 1
• Consider hospitalization 1
• Obtain renal ultrasound to evaluate for nephrocalcinosis 1, 6
• Treatment may include hydration, loop diuretics, corticosteroids, or bisphosphonates for severe cases

Prognosis and Follow-up

SCFN is self-limited in most cases:

• Cutaneous nodules typically resolve within 6 months without intervention 2, 3
• Surgical excision is rarely indicated and reserved only for severe cases with persistent symptomatic masses 7
• The critical management focus is preventing and treating hypercalcemia-related complications, not the skin lesions themselves 1, 4

Common Pitfalls to Avoid

• Failing to monitor calcium levels in a neonate with suspected SCFN, given the 100% incidence of hypercalcemia in monitored cases 1
• Discontinuing calcium monitoring before 3 months of age 1
• Performing unnecessary biopsy when clinical presentation and ultrasound are characteristic of SCFN 2
• Misdiagnosing as lipoma when risk factors and clinical presentation clearly indicate SCFN 2, 3